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Abstract 
A series of dibenzo[b,e]ox(thi)epin-11(6H)-one  O-benzoyloximes  has been 
synthesized and structurally elucidated by means of IR, 
1H-NMR, 
13C-NMR, MS, 
and  elemental analysis.  The newly developed compounds were screened at 
concentrations of 200–25 μg/mL for their antibacterial activity against Gram+ve 
organisms such as Methicillin-Resistant Staphylococcus Aureus  (MRSA), 
Gram–ve organisms such as Escherichia coli  (E. coli), and at the same 
concentration range for their antifungal activity against fungal strain Aspergillus 
niger  (A. niger) by the cup plate method.  Ofloxacin and ketoconazole 
(10 μg/mL) were used as reference standards for antibacterial and antifungal 
activity, respectively. The dibenzo[b,e]oxepines  6a–c  and  6e–h  showed low 
antimicrobial activity (MIC 125–200  μg/mL) compared to the reference 
substances, whereas a major improvement (MIC 50–75 μg/mL) was achieved 
with the synthesis of the corresponding bromomethyl derivative 6d. Moreover, 
replacement of oxygen by its bioisosteric sulfur led to isomeric dibenzo[b,e]thi-
epine derivatives 6g,h which significantly exhibited higher antimicrobial activity 
(MIC 25–50 μg/mL) against all tested culture strains used in the present study, 
demonstrating that a change  of chemical class from dibenzo[b,e]oxepine  to 
dibenzo[b,e]thiepine significantly improves the antimicrobial activity. Further 
variation, such as the oxidation of the thiepine sulfur  to  the corresponding 750  B. Sadek et al.:   
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isomeric  dibenzo[b,e]thiepine  5,5-dioxide  derivative  9,  comparatively  failed to 
exhibit high activity (MIC 200 μg/mL) against S. aureus, E. coli or A. niger. 
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Introduction 
The emergence of the antimicrobials resistance and multiresistance of bacterial and fungal 
infectious agents has urged the research for new antimicrobial substances and for new 
strategies for the treatment of infectious diseases which still remain a top public health 
problem in the world. The aim of this study was to evaluate the in vitro antimicrobial activity 
of some newly synthesized dibenzo[b,e]oxepin-11(6H)-one oxime  derivatives  which 
constitutes the fundamental structure of many products with biological activity including 
antidepressant [1–4], antipsychotic [5], antiinflammatory [6, 7], antibacterial and antifungal, 
and antidepressant activity [8]. Based on the facts that oximes and their derivatives have 
attracted considerable attention since the past few decades due to their chemotherapeutic 
value, as they were found to be antihyperglycemic [9], anti-neoplastic [10], anti-inflamma-
tory [11], and antimicrobial [12], and in continuation of our investigations on the class of 
dibenzo[b,e]oxepines with potential pharmacological properties, the new series of isomeric 
dibenzo[b,e]oxepin-11(6H)-one  O-benzoyloximes  and  dibenzo[b,e]thiepin-11(6H)-one 
O-benzoyloximes substituted with a methyl group at 2-position of dibenzo[b,e]ox(thi)epine 
nucleus has been synthesized and screened for the first time on antimicrobial activity [13].  
Results and Discussion 
Chemistry 
The synthesis of title compounds was achieved in three stages. 
First Stage: Synthesis of 2-(phenoxymethyl)benzoic acids (3a–f) 
In the first stage, the substituted 2-(phenoxymethyl)benzoic acids (3a–f) were prepared by 
treating the phthalide (1) with correspondingly substituted potassium phenoxide (2a–f) in 
xylene. The resulted potassium salts of 2-(phenoxymethyl)benzoic acid or 2-[(4-methyl-
phenoxy)methyl]benzoic acid  showed a good solubility in an aqueous solution of 10% 
potassium hydroxide and were separated from xylene through precipitation upon 
acidification using a mineral acid solution. The potassium salts 2a–b  and of 
p-methylphenol 2c–f were obtained using the corresponding phenol or p-methylphenol and 
potassium hydroxide in xylene, and the resulting water was removed by azeotropic 
distillation (Scheme 1).  
Second Stage: Synthesis of dibenzo[b,e]oxepin-11(6H)-one (4a–h) 
The intermediates 4a–f  were synthesized by a Friedel-Crafts cyclization of the corre-
sponding (phenoxymethyl)benzoyl chloride or 4-[(4-methylphenoxy)methyl]benzoic acid in 
dry 1,2-dichloroethane. The acid chlorides were obtained by refluxing the 3a–f with thionyl   Synthesis and Antimicrobial Evaluation of Dibenzo[b,e]oxepin-11(6H)-one O-Benzoyloxime …  751 
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chloride in a 25 percentage excess and were instantly used in the next step without further 
purification (Scheme 1).  
Third Stage: Synthesis of (E/Z)-dibenzo[b,e]oxepin-11(6H)-one O-benzoyloximes 
derivatives (6a–f)  
Compounds 6a–f (E and Z) were prepared by acylation of the correspondingly 2-sustituted 
oxime intermediates 5a–f with different benzoyl chlorides in dry benzene under catalysis of 
anhydrous pyridine as a proton acceptor. The oxime intermediates 5a–f were obtained by 
treating the ketones 4a–f with hydroxylamine hydrochloride in the presence of pyridine. 
The reactions are presented in the Scheme 1 and the structures of the new compounds 
(6a–h) are presented in Table 1.  
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Sch. 1.   Synthesis of compounds 6a–f. 
i: xylene, reflux, 5 h, 1 N NaOH, 1 M HCl;  
ii: a) SOCl2, reflux, 3 h; b) AlCl3, 0–5°C; c) stirring, 5–20°C, 1 h;  
iii: Pyridine, NH2OH·HCl, reflux, 96 h;  
iv: anhyd. benzene, pyridine, corresp. substituted benzoylchloride, reflux 2 h.  
The synthesis of dibenzo[b,e]thiepin-11(6H)-one O-benzoyloximes 6g,h and dibenzo[b,e]-
thiepin-11(6H)-one 5,5-dioxide (sulfone) 9 was performed in several stages. In the first 
stage, the  reaction of phthalide  (1)  with potassium salts of thiophenol 2g  or  p-methyl-
thiophenol 2h resulted in 2-[(phenylthio)methyl]benzoic acid (3g) and 2-{[(4-methylphenyl)-
thio]methyl}benzoic acid (3h), respectively. These acids were cyclized with polyphosphoric 
acid to the desired dibenzo[b,e]thiepin-11(6H)-one oxime  4g  and  its corresponding 
2-methyl derivate 4h. In the second stage, the ketones 4g–h were converted to the corre-
sponding oxime  intermediates  5g–h  upon treatment with hydroxylamine hydrochloride. 
The third stage comprised the acylation of oximes 5g–h with various acid chlorides and 
afforded the new dibenzo[b,e]thiepin-11(6H)-one O-benzoyloximes 6g,h (Scheme 2).  752  B. Sadek et al.:   
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Sch. 2.   Synthesis of compounds 6g,h. 
i: xylene, reflux, 5 h, 1N NaOH, 1 M HCl;  
ii: a) polyphorphoric acid, 80°C during addition of 3g or 3h; b) for intermediate 
4g: 100–110°C, 1h, and for intermediate 4h: 140–150°C, 2.5 h; c) 80°C, 
ice-water, 1 N NaOH;  
iii: pyridine, NH2OH·HCl, reflux, 24 h;  
iv: anhydr. benzene, pyridine, corresp. substituted benzoylchloride, reflux 2 h.  
For synthesis of compound 9, 2-methyldibenzo[b,e]thiepin-11(6H)-one (4h)  and 
molybdenum trioxide were dissolved in ethanol, and upon addition of 30% aqueous 
hydrogenperoxide, the mixture was refluxed for 53 min. Water was added to the reaction 
mixture and the solid residue was filtered and recrystallized from ethanol to obtain the 
intermediate  2-methyldibenzo[b,e]thiepin-11(6H)-one 5,5-dioxide  (7)  which has been 
instantly converted to the oxime intermediate 8  by treatment with hydroxylamine 
hydrochloride in presence of anhydrous pyridine. 2-Methyldibenzo[b,e]thiepin-11(6H)-one 
O-benzoyloxime 5,5-dioxide (9)  was prepared through an acylation reaction of 8  with 
benzoyl  chloride under catalytic presence of anhydrous pyridine in absolute benzene 
(Scheme 3). 
The structures 6a–h and 9 were assigned to the isolated products on the basis of their 
elemental analyses and their high-field 
1H- and 
13C-NMR, IR, and mass spectral data. 
TLC, 
1H and 
13C NMR showed 2 isomers of oximes (E/Z). The 
1H-NMR spectra of the new 
(E/Z)-dibenzo[b,e]ox(thi)epines are divided into two spectra, one corresponding to the 
ox(thi)epine  system and another to the acyl radical attached to the oxime  group.  The 
presence of oxygen in 5-position favors the existence of E/Z isomerism which results in 
spectra with the dedoublation of the protons and the carbon signals. The protons of the 
methyl group situated in 2-position of dibenzo[b,e]ox(thi)epine nucleus give in the majority 
a broad singlet signal in the range of 2.48–2.29 ppm, and in theminority a singlet signal in 
the range 2.46–2.25 ppm. In addition, the protons of the methylene group (H-6) of the 
derivatives 6a–h and 9 give a singlet signal in the range of 5.31–5.10 ppm, and a broad   Synthesis and Antimicrobial Evaluation of Dibenzo[b,e]oxepin-11(6H)-one O-Benzoyloxime …  753 
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singlet signal in the range of 5.21–4.47 ppm, providing additional evidence for the 
existence of E/Z  isomerism in titled compounds. Moreover, analysis of the 
13C-NMR 
spectra of 6a, 6e, and 6g indicated that the methylene group (C6) appears in majority (
M) 
by 70.60 ppm and in minority (
m) by 70.71, and the differences between the chemical shifts 
of the two E/Z isomers were found to be insignificant. Regarding the 
13C-NMR analysis, 
the carbon atom C1 in the oxepine system is the most screened carbon atom, and the C11 
is the most unscreened carbon atom and can be found in the range of 163.47–165.45. The 
signal corresponding to the C12 atom appears in the range of 161.5–164 ppm. The 
spectral data using 
1H-NMR and 
13C-NMR spectroscopy confirmed the structure of the 
obtained compounds as well as the existence of E/Z isomers. 
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Sch. 3.   Synthesis of compound 9. 
i: MoO3, ethanol, 30% H2O2, reflux, 53 minutes; 
ii: pyridine, NH2OH·HCl, reflux, 24 h;  
iv: anhydr. benzene, pyridine, benzoylchloride, reflux 2 h.  
Biological Activity 
The newly developed (E/Z)-dibenzo[b,e]ox(thi)epine  derivatives  were tested at concen-
trations of 200–25 μg/mL for their antibacterial activity against Gram+ve organisms such 
as methicillin-resistant  Staphylococcus aureus  (MRSA), Gram–ve organisms such as 
Escherichia coli (E. coli), and at the same concentration range for their antifungal activity 
against fungal strain Aspergillus niger (A. niger) by the cup plate method [14]. Ofloxacin 
and ketoconazole (10 μg/mL) were purchased from Wuhan Konglong Century Technology 
Development Co., Ltd. (Wuhan, China), and were used as reference standards for 
antibacterial and antifungal activity, respectively. The obtained in vitro antimicrobial results 
are listed in Table 1.  754  B. Sadek et al.:   
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Tab. 1.   In vitro antimicrobial activity of the title compounds 
6
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        MIC µg/mL 
Compound  X  R
1  R
2  S. aureus  E. coli  A. niger 
6a  O  H 
17
16
18
15
13
14 I 
200  200  200 
6b  O  H 
17
16
18
15
13
14 OMe
OMe
OMe  
150  200  150 
6c  O  CH3 
17
16
18
15
13
14 I 
125  150  125 
6d  O  CH3 
17
16
18
15
13
14 Br
 
75  75  50 
6e  O  CH3 
17
16
18
15
13
14
O2N
 
125  125  150 
6f  O  CH3 
17
16
18
15
13
14 OMe
OMe
OMe  
200  200  200 
6g  S  H 
17
16
18
15
13
14 Cl 
50  25  25 
6h  S  H 
17
16
18
15
13
14 Br 
50  50  25 
9  SO2  CH3 
17
16
18
15
13
14
 
200  200  200 
Ofloxacin  –  –  –  10  12.5  – 
Ketoconazole  –  –  –  –  –  12.5 
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Despite the diversity of substituents at 2-position of the dibenzo[b,e]oxepine ring or the 
variety of O-benzoyl groups realized in derivatives 6a–c and 6e,f, low antimicrobial activity 
(MIC 125–200 μg/mL) compared to the reference substances Ofloxacin and Ketoconazole, 
was observed. Based on the investigation of integrals obtained for the protons (H-6) in the 
1HNMR spectra of the derivatives 6a–c and 6e,f, a mixture of about 1:1.5 ratio was found 
and indicated the presence of one isomer (E- or Z-isomer) in majority, and might be the 
reason for the low antimicrobial activity observed. Major improvement in antimicrobial 
activity  was obtained with the development of compound  6d. Within this homogenous 
series, the O-benzoyl moiety bearing a bromomethyl function at p-position seemed to be 
optimal in  exhibiting  antimicrobial activity with MIC of 75 μg/mL against E. coli and A. 
niger, and a MIC of 50 μg/mL against S. aureus. A metabolic process within bacterial and 
fungal cells expected to be easier for 6d, since an aromatic methylene group bearing a 
strong electron-withdrawing brome is present and might be an explanation for the 
increased antimicrobial activity obtained for 6d, as the ration (E/Z or Z/E) was found to be 
similar to that of 6a–c and 6e–f. In contrast, the development of sulfur bioisosteres led to 
the dibenzo[b,e]thiepine derivatives 6g,h which significantly exhibited higher antimicrobial 
activity (MIC 25–50 μg/mL) against all tested culture strains used in the present study, 
indicating that changes of the heteroatom at 5-positon of the  dibenzo[b,e]oxepine  ring 
obviously improves the antimicrobial activity. Moreover, the racemic mixture of 1:1 ratio 
obtained indicates that the quantity of one isomeric form (E or Z), which was found in 
minority for 6a–f, is increased in 6g and 6h. The later finding signifies that the antimicrobial 
activity is also influenced by E/Z-isomerism and is assigned to only one specific isomer of 
titled compounds. On the other hand, an introduction of a sulfonyl moiety at 5-position 
resulted in compound 9  with 1:1 ratio (E/Z) which comparatively failed to exhibit 
antimicrobial activity (MIC 200 μg/mL) against S. aureus, E. coli or A. niger, demonstrating 
the negative impact of the sulfonyl group on the antimicrobial activity of titled compounds, 
apart from of the geometric isomerism present in compound 9 (Table 1).  
Experimental 
General procedures 
Melting points are uncorrected and determined in open capillaries in a Buechi 512 Dr. 
Tottoli apparatus. 
1H-NMR spectra were recorded on a Bruker WC 300 spectrometer with 
tetramethylsilane (TMS) as internal standard. Chemical shifts are reported in ppm 
downfield from internal tetramethylsilane as reference. 
1H-NMR signals are reported in 
order: multiplicity (s…singlet; d…doublet; t…triplet; m…multiplet; *…exchangeable by 
D2O), number of protons, and approximate coupling constants in Hertz. For compounds 
6a, 6e, and 6g a 
13C-NMR spectrum was recorded on a Bruker DPX 400 Avance (100 
MHz) instrument and chemical shifts are reported in ppm downfield from internal 
tetramethylsilane used as reference. Elemental analyses were performed on Perkin-Elmer 
240B and 240C instruments. Analyses (C, H, N) indicated by the symbols of elements 
were within ±0.4% of the theoretical values. Chromatographic separations were done 
using a Chromatotron Model 7924 (Harrison Research) with 4 mm layers of silica gel 60 
PF containing gypsum (Merck). EI-mass spectra were recorded using Finnigan MAT CH7A 
(70 eV), Finnigan MAT 711 (80 eV), or Kratos MS 25 RF (70 eV) instruments. 
+FAB-MS 
spectra were recorded on Finnigan MAT CH5DF instrument (xenon, DMSO)/glycerol).  
 756  B. Sadek et al.:   
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Chemistry 
Synthesis of 2-(phenoxymethyl)benzoic acid  (3a,b) and 2-[(4-methylphenoxy)methyl]-
benzoic acid 3c–f 
A solution containing 0.05 mol of phenol for intermediates 3a and 3b, p-methylphenol for 
intermediates 3c–f in 30 mL xylene was placed in a round-bottomed flask equipped with a 
Dean-Stark trap device. Subsequently, potassium hydroxide (0.055 mol) was added, and 
the reaction mixture was refluxed while the resulting water was removed by azeotropic 
distillation, and potassium salts 2a–f were precipitated. Phthalide (1, 0.05 mol) was added 
and the mixture and refluxed until it solidifies. The precipitate was heated for solubilization 
with 10% potassium hydroxide solution and finally diluted with water (50 mL). The aqueous 
phase was separated and acidified with 1M hydrochloric acid solution until the mixture 
became acidic (pH 3), and benzoic acid intermediates 3a–f  were precipitated. The 
precipitate of each intermediate of 3a–f  was crystallized from a mixture of 
water/isopropanol (1:3) and shows a 49% yield. In the following step, each intermediate of 
3a–f (0.02 mol) was refluxed for three hours, and excess thionyl chloride together with the 
solvent were removed by reduced pressure, and the resulted benzoic acid chlorides in 
their crude status were used in the next step to prepare 4a–f.  
Synthesis of dibenzo[b,e]oxepin-11(6H)-ones 4a–f 
A suspension of benzoic acid chloride (0.02 mol) of each intermediate 3a–f in 1,2-dichloro-
ethane (25 mL), was added in portions to a  stirring  anhydrous aluminium chloride 
(0.02 mol) suspended in 1,2-dichloroethane (15 mL) which was maintained cooled at   
0–5°C during the addition period. After the corresponding acid chloride was added, the 
reaction mixture was stirred at 5–20°C for one hour and then for another hour at 20°C. The 
mixture was then poured into 5% hydrochloric acid solution and stirred for one hour, the 
organic and aqueous layers were separated, washed once with 5% sodium hydroxide 
solution and twice with water, dried with anhydrous calcium chloride, treated with 
decolorizing charcoal, and evaporated under vacuum to yield the intermediates 4a–f which 
were recrystallized from hexane in a 59% yield. 
Synthesis of dibenzo[b,e]oxepin-11-(6H)-one O-benzoyloximes 6a–f 
For synthesis of target compounds 6a–f, each of the precursors 4a–f  (0.05 mol) and 
hydroxylamine hydrochloride (0.15 mol) were boiled under reflux in pyridine (100 mL) for 
96 h. The pyridine is subsequently distilled off in vacuum, and the resulted residue of 5a–f 
was triturated with water, suction-filtered, dried and recrystallized from isopropanol in a 
54% yield. In the following step, to a suspension of the corresponding intermediate 5a–f 
(0.016 mol) in anhydrous benzene, a solution of correspondingly substituted benzoyl 
chloride (0.016 mol) in anhydrous benzene (10 mL)  and dry pyridine (0.016 mol) was 
added dropwise and the mixture was refluxed for two hours. After cooling and filtration, the 
solvent was removed by distillation and the residue was triturated with isopropanol. The 
resulting solid was recrystallized from isopropanol to yield the title compounds 6a–f. 
Dibenzo[b,e]oxepin-11(6H)-one O-(4-iodobenzoyl)oxime (6a)  
Yield: 73%, m.p.: 168.9–171.6 °C; IR (KBr): ν(cm
−1) 2878 (CH2-O), 1739 (C=O oxime 
carbamate), 1585 (C=N); 
1H-NMR (CDCl3): δ ppm = 7.77 (d, 2H, H-14, H-18, 8.6), 7.58 (d, 
2H, H-15, H-17, 8.6), 7.46-7.51 (m, 4H, H-7, H-8, H-9, H-10), 7.37 (d, 1H, H-1, 3.1), 6.96   Synthesis and Antimicrobial Evaluation of Dibenzo[b,e]oxepin-11(6H)-one O-Benzoyloxime …  757 
Sci Pharm. 2011; 79: 749–761 
(dd, 1H, H-3, 9.0, 3.1), 6.84 (d, 1H, H-4, 8.9), 6.61 (dd, 1H, H-2, 6.61), 5.24, 5.20 (s, bs, 
2H, H-6); 
13C-NMR (CDCl3) δ ppm = 164.50 (C-11), 163.10 (C-12), 153.81 (C-4a), 137.90 
(CH-15 and CH-17), 136.10 (C-3), 133.10 (C-10a), 131.0 (CH-14 and CH-18), 130.50 (C-
8), 128.90 (C-2), 128.20 (CH-9), 128.10 (CH-13), 128.0 (C-7), 127.90 (C-10), 120.70 (C-
4), 119.20 (C-1a), 113.0 (C-1), 101.30 (C-16), 70.71
m (C-6), 70.60
M (C-6), 20.74 (C-19); 
MS: m/z (%) 456 (M
+, 10), 211 (13), 210 (100); Anal. Calcd. For C21H14INO3: C, 55.40; H, 
3.10; N, 3.08. Found: C, 55.52; H, 3.34; N, 3.01.  
Dibenzo[b,e]oxepin-11(6H)-one O-(3,4,5-trimethoxy benzoyl)oxime (6b)  
Yield:  76%, m.p.: 182.4–185.1 °C; IR (KBr): ν(cm
−1) 2837 (CH2-O), 1750 (C=O oxime 
carbamate), 1589 (C=N); 
1H-NMR (CDCl3): δ ppm = 7.46-7.51 (m, 4H, H-7, H-8, H-9, H-
10), 7.37 (d, 1H, H-1, 3.1), 7.01 (d, 2H, H-14, H-18, 8.6), 6.96 (dd, 1H, H-3, 9.0, 3.1), 6.84 
(d, 1H, H-4, 8.9), 6.61 (dd, 1H, H-2, 6.61), 5.23, 5.19 (s, bs, 2H, H-6), 3.91, 3.89, 3.84, 
3.80 (4*s, 9H, 4*OCH3); MS: m/z (%) 420 (M
+, 11), 230 (29), 211 (13), 210 (100); Anal. 
Calcd. For C24H21NO6: C, 55.40; H, 3.10; N, 3.08. Found: C, 55.52; H, 3.34; N, 3.01. 
2-Methyldibenzo[b,e]oxepin-11(6H)-one O-(4-iodobenzoyl)oxime (6c)  
Yield: 81%, m.p.: 156.4–159 °C; IR (KBr): ν(cm
−1) 2912 (CH2-O), 1755 (C=O oxime 
carbamate), 1586 (C=N); 
1H-NMR (CDCl3): δ ppm = 7.77 (d, 2H, H-14, H-18, 8.6), 7.62 
(bs, 1H, H-1), 7.58 (d, 2H, H-15, H-17, 8.6), 7.46-7.51 (m, 4H, H-7, H-8, H-9, H-10), 7.08 
(bdd, 1H, H-3, 8.1, 1.9), 7.00 (d, 1H, H-4, 8.1), 5.24, 5.20 (s, bs, 2H, H-6), 2.29, 2.26 (bs, 
s, 3H, CH3); MS: m/z (%) 470 (M
+, 16), 225 (15), 224 (100); Anal. Calcd. For C22H16INO3 · 
½ H2O: C, 55.23; H, 3.55; N, 2.93. Found: C, 55.63; H, 3.68; N, 2.83. 
2-Methyldibenzo[b,e]oxepin-11(6H)-one O-[4-(bromomethyl)benzoyl]oxime (6d)  
Yield: 65%, m.p.: 189.1–190 °C; IR (KBr): ν(cm
−1) 3029 (CH2-Br), 2925 (CH2-O), 1744 
(C=O oxime carbamate), 1612 (C=N); 
1H-NMR (CDCl3): δ ppm = 8.04 (d, 2H, H-14, H-18, 
8.6), 7.85 (d, 2H, H-15, H-17), 7.62 (bs, 1H, H-1), 7.46-7.51 (m, 4H, H-7, H-8, H-9, H-10), 
7.08 (bdd, 1H, H-3, 8.1, 1.9), 7.00 (d, 1H, H-4, 8.1), 5.23, 5.17 (s, bs, 2H, H-6), 4.62, 4.59 
(bs, s, 2H, CH2Br), 2.34, 2.32 (bs, s, 3H, CH3); MS: m/z (%) 436 (M
+, 12), 225 (15), 224 
(100); Anal. Calcd. For C23H18BrNO3: C, 55.23; H, 3.45; N, 2.93. Found: C, 55.63; H, 3.68; 
N, 2.83. 
2-Methyldibenzo[b,e]oxepin-11(6H)-one O-(2-nitrobenzoyl)oxime (6e)  
Yield: 81%, m.p.: 174.5–177.8 °C; IR (KBr): ν(cm
−1) 2921 (CH2-O), 1757 (C=O oxime 
carbamate), 1596 (C=N); 
1H-NMR (CDCl3): δ ppm = 7.90 (d, 1H, H-15, 7.6), 7.61-7.53 (m, 
3H, H-16, H-17, H-18), 7.36-7.19 (m, 4H, H-7, H-8, H-9, H-10), 7.14 (d, 1H, H-1, 3.2), 6.86 
(dd, 1H, H-3, 8.9, 3.0), 6.73 (d, 1H, H-4, 9.0), 5.10, 5.02 (s, bs, 2H, H-6), 2.31, 2.25 (bs, s, 
3H, CH3); 
13C-NMR (CDCl3) δ ppm = 165.45 (C-11), 161.50 (C-12), 153.93 (C-4a), 148.30 
(CH-15), 130.87 (C-9), 129.89 (CH-17), 128.94 (C-2), 128.65 (C-7), 128.57 (C-8), 127.94 
(C-10), 127.80 (C-13), 127.75 (CH-16), 124.60 (CH-14), 121.21 (C-4), 120.90 (C-3), 
119.08 (C-1a), 113.14 (C-1), 70.71
m (C-6), 70.60
M (C-6); MS: m/z (%) 489 (M
+, 25), 240 
(11), 225 (15), 224 (100); Anal. Calcd. For C22H16N2O5 · ½ H2O: C, 66.48; H, 4.28; N, 7.05. 
Found: C, 66.84; H, 4.37; N, 6.86. 
2-Methyldibenzo[b,e]oxepin-11(6H)-one O-(3,4,5-trimethoxy benzoyl)oxime (6f)  
Yield: 79%, m.p.: 185.3–187.1 °C; IR (KBr): ν(cm
−1) 2938 (CH2-O), 1753 (C=O oxime 758  B. Sadek et al.:   
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carbamate), 1591 (C=N); 
1H-NMR (CDCl3): δ ppm = 7.46-7.51 (m, 4H, H-7, H-8, H-9, H-
10), 7.14 (d, 1H, H-1, 3.2), 7.01 (d, 2H, H-14, H-18, 8.6), 6.86 (dd, 1H, H-3, 8.9, 3.0), 6.73 
(d, 1H, H-4, 9.0), 5.23, 5.19 (s, bs, 2H, H-6), 3.91, 3.89, 3.84, 3.80 (4*s, 9H, 4*OCH3), 
2.31, 2.29 (bs, s, 3H, CH3); MS: m/z (%) 434 (M
+, 17), 230 (46), 225 (14), 224 (100); Anal. 
Calcd. For C25H23NO6: C, 67.85; H, 5.43; N, 3.17. Found: C, 68.06; H, 5.23; N, 3.05. 
2-[(Phenylthio)methyl]benzoic acid (3g)  
For synthesis of 3g, 0.1 mol potassium hydroxide was added to a solution of 0.1 mol 
thiophenol in 60 mL xylene and refluxed until 2 mL of water were removed. Upon addition 
of 0.1 mol phthalide, the mixture was refluxed for 3h, cooled, and the solidified mixture was 
dissolved in 10% potassium hydroxide and diluted with 100 mL water. The aqueous phase 
was separated and acidified 1M hydrochloric acid (pH= 3) to afford 3g which was filtered 
and recrystallized from aqueous ethanol. 
2-[4-Tolylthio)methyl]benzoic acid  
(2-{[(4-Methylphenyl)sulfanyl]methyl}benzoic acid, 3h) 
Similarly to the synthesis of 3g,  2-[4-tolylthio)methyl]benzoic acid  (3h)  was achieved 
through the reaction of 0.1 mol p-(methyl)thiophenol and 0.1 mol phthalide, and re-
crystallization from aqueous ethanol. 
Dibenzo[b,e]thiepin-11(6H)-one (4g) 
140 g polyphosphoric acid was heated to 80°C  and 0.1 mol of 2-[(Phenylthio)methyl]-
benzoic acid 3g were slowly added under stirring, and the mixture was heated for one hour 
to 100–110°C. After partial cooling (80°C), ice and water were added, product 4g was 
extracted with dichloromethane and washed with water and 5% sodium hydroxide. The 
solvent was removed under vacuum and the residue recrystallized from isopropanol and 
used in the next step without further characterization. 
2-Methyldibenzo[b,e]thiepin-11(6H)-one (4h) 
Cyclodehydration of 2-[4-tolylthio)methyl]benzoic acid  (3h; 0.1 mol) in the presence of 
polyphosphoric acid, by heating for 2.5 h to 140–150°C was carried out similarly to the 
procedure of 4g; the crude product 4h was recrystallized from ethanol, and used in the 
following step without further characterization. 
Dibenzo[b,e]thiepin-11(6H)-one oximes 5g and 5h 
For the synthesis of 5g  and  5h, a mixture of 0.05 mol of corresponding  dibenzo[b,e]-
thiepin-11(6H)-one (4g) and 2-methyldibenzo[b,e]thiepin-11(6H)-one (4h) was refluxed for 
24h with 0.15 mol hydroxylamine hydrochloride in 100 mL of pyridine. The pyridine was 
subsequently removed under vacuum, the residue of the corresponding product 5g or 5h 
was triturated with water and filtered, dried and finally recrystallized from isopropanol. 
Bothe oxime intermediates  5g  and  5h  were used instantly in the next step of oxime 
acylation to afford the final compounds 6g and 6h in similarity to the procedure carried out 
for compounds 6a–f.  
Dibenzo[b,e]thiepin-11(6H)-one O-(4-chlorobenzoyl)oxime (6g)  
Yield: 83%, m.p.:  141.7–143 °C; IR (KBr): ν(cm
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carbamate), 1590 (C=N); 
1H-NMR (CDCl3): δ ppm = 7.77 (d, 2H, H-14, H-18, 8.7), 7.58 (d, 
2H, H-15, H-17, 8.7), 7.46-7.51 (m, 4H, H-7, H-8, H-9, H-10), 7.37 (d, 1H, H-1, 3.1), 6.96 
(dd, 1H, H-3, 9.0, 3.1), 6.84 (d, 1H, H-4, 8.9), 6.61 (dd, 1H, H-2, 6.61), 4.66, 4.20 (s, bs, 
2H, H-6); 
13C-NMR (CDCl3) δ ppm = 165.45 (C-11), 161.50 (C-12), 153.93 (C-4a), 148.30 
(CH-15), 131.80 (CH-18), 130.87 (C-9), 129.89 (CH-17), 128.94 (C-2), 128.65 (C-7), 
128.57 (C-8), 127.94 (C-10), 127.80 (CH-13), 127.75 (CH-16), 124.60 (CH-14), 121.21 
(C-4), 120.90 (C-3), 119.08 (C-1a), 113.14 (C-1), 70.71
m (C-6), 70.60
M (C-6), 20.75 (C-19); 
MS: m/z (%) 380 (M
+, 11), 227 (14), 226 (100), 185 (30); Anal. Calcd. For C21H14NO2SCl: 
C, 66.40; H, 3.71; N, 3.69. Found: C, 66.55; H, 3.72; N, 3.62. 
2-Methyldibenzo[b,e]thiepin-11(6H)-one O-(4-bromobenzoyl)oxime (6h)  
Yield: 79%, m.p.: 205–207 °C; IR (KBr): ν(cm
−1) 2966 (CH2-S), 1751 (C=O oxime 
carbamate), 1591 (C=N); 
1H-NMR (CDCl3): δ ppm = 7.77 (d, 2H, H-14, H-18, 8.6), 7.62 
(bs, 1H, H-1), 7.58 (d, 2H, H-15, H-17, 8.6), 7.46-7.51 (m, 4H, H-7, H-8, H-9, H-10), 7.08 
(bdd, 1H, H-3, 8.1, 1.9), 7.01 (d, 1H, H-4, 8.1), 4.66, 4.20 (s, bs, 2H, H-6), 2.29, 2.26 (bs, 
s, 3H, CH3); MS: m/z (%) 439 (M
+, 44), 437 (23), 241 (17), 240 (100); Anal. Calcd. For 
C22H16NO2SBr: C, 60.28; H, 3.68; N, 3.20. Found: C, 60.03; H, 3.35; N, 3.14. 
2-Methyldibenzo[b,e]thiepin-11(6H)-one O-benzoyloxime 5,5-dioxide (9) 
To a mixture of 2-methyldibenzo[b,e]thioepin-11(6H)-one (4h, 1 mmol) and MoO3 (0.05 
mmol, 0.007g) in EtOH (2ml), 30% aq. H2O2  (0.3 ml, 2.67 mmol) was added and the 
mixture was refluxed for 53 min. After completion of the reaction, water (15 mL) was added 
and the reaction mixture was filtered. The solid residue was recrystallized from ethanol to 
obtain a pure product of 2-methyldibenzo[b,e]thiepin-11(6H)-one 5,5-dioxide (7) in 97% 
yield.  The oxime intermediate 8  was prepared through treatment of 7  (1 mmol) with 
hydroxylamine hydrochloride (2 mmol) in presence of anhydrous pyridine. The desired 
product  9  was achieved through an acylation reaction of 2-methyldibenzo[b,e]thiepin-
11(6H)-one  oxime  5,5-dioxide  (8, 1 mmol) with benzoyl  chloride (1  mmol) in absolute 
benzene, and under catalytic presence of anhydrous pyridine.  
Yield: 65%, m.p.: 183.5–185 °C; IR (KBr): ν(cm
−1) 2926 (CH2-SO2), 1758 (C=O oxime 
carbamate), 1560 (C=N); 
1H-NMR (CDCl3): δ ppm = 7.72-7.62 (m, 6H, H-1, H-14, H-15, H-
16, H-17, H-18), 7.46-7.51 (m, 4H, H-7, H-8, H-9, H-10), 7.08 (bdd, 1H, H-3, 8.1, 1.9), 7.01 
(d, 1H, H-4, 8.1), 5.31, 4.47 (bs, bs, 2H, H-6), 2.48, 2.46 (bs, s, 3H, CH3); MS: m/z (%) 392 
(M
+, 4), 275 (11), 260 (10), 258 (100); Anal. Calcd. For C22H17NO4S: C, 67.52; H, 4.35; N, 
3.80. Found: C, 67.58; H, 4.40; N, 3.44. 
Antimicrobial Activity 
The quantitative in vitro  antimicrobial study was carried on Muller-Hinton agar (Hi-media) 
plates (37 °C,  24 h) by the agar diffusion  cup plate method [14]. The compounds   
(200–25 μg/mL)  were  screened  for  antimicrobial  activity  against  the  bacterial  strains 
Staphylococcus aureus ATCC 25923 (S. aureus) (Gram+ve) and Escherchia coli ATCC 
35218 (E. coli) (Gram-ve). Antifungal activity was tested on Sabouraud dextrose agar (Hi-
media) plates (26 °C, 48–72 h) by the cup plate method against Aspergillus niger A733 (A. 
niger) also at a concentration level of 200–25 μg/mL. Ofloxacin and ketoconazole were 
used as standards for comparison of antibacterial and antifungal activity under the similar 
conditions. DMF was used as a solvent control for both antibacterial and antifungal 760  B. Sadek et al.:   
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activities, and the results are presented in minimal inhibition concentration (MIC) values 
(μg/mL) in Table 1.  
Conclusion 
The new  E/Z-compounds 6a–h and 9 clearly differ in their corresponding antimicrobial 
activity depending on the type of substitution and that of the geometric ratio obtained for 
the titled compounds. Among the dibenzo[b,e]oxepines 6a–f (ratio of E/Z or Z/E 1:1.5) 
developed in the course of this study, particularly 6d which is possessing a bromomethyl 
substitution at p-position of O-benzoyloxime  moiety was identified as exhibiting  high 
antibacterial activity against methicillin-resistant  S. aureus (Gram positive) and E. coli 
(Gram negative) bacteria and antifungal activity against A. niger. However, the isomeric 
dibenzo[b,e]thiepine derivatives 6g and 6h (ratio of E/Z 1:1) were found to be highest in 
their antibacterial activity. On the other hand, an  introduction of a sulfonyl moiety at 
5-position resulted in compound 9  with 1:1 ratio (E/Z) which, despite the geometric 
isomerism present, comparatively failed to exhibit antimicrobial activity (MIC 200 μg/mL) 
against S. aureus, E. coli or A. niger, demonstrating the negative impact of sulfonyl group 
on the antimicrobial  activity of titled compounds.  These distinct in vitro antimicrobial 
results, combined with the potential benefits or at least differences in geometric isomerism 
and  pharmacokinetics,  make the titled (E/Z)-dibenzo[b,e]ox(thi)epin-11(6H)-one 
O-benzoyloxime derivatives not only interesting leads for the further chemical geometrical 
separation of E-  and  Z–isomers within this  series  but also potentially interesting for 
additional structure-activity relationship studies. 
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